Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients

NCT06890078 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2025-07-08
Last updated
2026-04-23

Condition(s) studied

PneumocystisImmunocompromised Patients

Investigational drug(s) / intervention(s)

Biological sampling

Biological sampling: Mouthwash, nasopharyngeal swab, blood sampling

Study summary

Evaluate new diagnostic methods using qPCR on non-invasive samples, compared with reference techniques for the positive diagnosis of pneumocystis (PcP) in immunocompromised patients

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * adult patients with suspected pneumocystis * with an indication for bronchial fibroscopy for BAL or induced sputum * no opposition to the research from the adult patient or his or her next of kin research for patients unable to express their non-opposition Exclusion Criteria: * Pneumocystis treated for more than 72 hours * pregnancy/breast-feeding * adult patients deprived of liberty, protected

Primary outcome measure(s)

  • Pearson correlation coefficient — At inclusion
    Pearson correlation coefficient between the fungal load obtained by PCR on nasopharyngeal swabs nasopharyngeal swab and buccal lavage and that obtained by reference samples (induced sputum or BAL) in patients with confirmed PcP.

Trial sites (4)

FacilityCityRegionStatus
Hôpital Lariboisière AP-HP Maladies infectieuses Paris France Recruiting
Hôpital Saint Louis AP-HP Maladies infectieuses Paris France Recruiting
Hôpital Saint Louis AP-HP Réanimation Paris France Recruiting
Hôpital Saint-Louis AP-HP Pneumologie Paris France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06890078 on ClinicalTrials.gov ↗ ← All trials in France